Colorectal Cancer Update - 1 | 2008

You are here: Home: Audio Program Guide: CCU 1 | 2008: CCU 1 | 2008 Audio

Go to interview with Michael J O’Connell, MD
Go to interview with John L Marshall, MD
Go to interview with Jeffrey A Meyerhardt, MD, MPH

To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Michael J O’Connell, MD
Associate Chairman
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pittsburgh, Pennsylvania

Click here to download the entire interview

Track 1

Molecular diagnostics to identify patients at high risk for colorectal cancer; potential chemoprevention agents

Track 2

Use of neoadjuvant chemoradiation therapy to downstage rectal tumors

Track 3

NSABP-R-04: Preoperative radiation therapy and either capecitabine or 5-FU, with or without oxaliplatin, for patients with operable rectal cancer

Track 4

Off-protocol use of neoadjuvant oxaliplatin and capecitabine for rectal cancer

Track 5

NSABP-C-08: A Phase III trial evaluating adjuvant FOLFOX with or without bevacizumab — Initial
safety data

Track 6

AVANT: A Phase III adjuvant trial comparing FOLFOX to FOLFOX/bevacizumab and CAPOX/ bevacizumab for colon cancer

Track 7

Bevacizumab versus cetuximab as first-line therapy for metastatic disease

Track 8

K-ras mutation status and benefit in a clinical trial comparing panitumumab to best supportive care

Track 9

Identifying predictors of response to anti-angiogenic agents

Track 10

Interpreting the negative results of the PACCE trial of FOLFOX with bevacizumab and panitumumab

Track 11

Clinical trials evaluating chemotherapy with bevacizumab and cetuximab

Track 12

RT-PCR assay to identify patients with Stage II disease at high risk for recurrence

Track 13

Development of future therapies based on molecular pathways and biologic profiles

Track 14

Adjuvant Colon Cancer Endpoints (ACCENT) data: Survival after recurrence

Track 15

ACCENT data on the recurrence pattern of colon cancer


	John L Marshall, MD Chief, Hematology and Oncology Director of Developmental Therapeutics and GI Oncology Lombardi Comprehensive Cancer Center Georgetown University Washington, DC

Click here to download the entire interview

Track 1

Physician attitudes about adjuvant therapy for patients versus themselves

Track 2

NSABP-C-08: Impact of adjuvant bevacizumab on quality of life

Track 3

Bowel perforation and vascular events associated with bevacizumab

Track 4

Incorporating bevacizumab into adjuvant trials

Track 5

Roles of the surgeon and the pathologist in lymph node sampling

Track 6

MOSAIC data and the controversy about adjuvant chemotherapy for Stage II versus Stage III disease

Track 7

Dosing capecitabine in the adjuvant and metastatic settings

Track 8

Clinical use of capecitabine in the adjuvant setting

Track 9

Front-line therapy for metastatic disease in clinical practice

Track 10

Optimal dose of bevacizumab

Track 11

iBET: Continuation of bevacizumab upon disease progression

Track 12

Patterns of care in treating the elderly

Track 13

Clinical approach to synchronous primary and metastatic disease

Track 14

Controversies and clinical trial data regarding drug holidays

Track 15

Future Phase II trial of sunitinib with capecitabine

Track 16

Neoadjuvant therapy for rectal cancer

Track 17

Treating a public figure who has metastatic disease


	Jeffrey A Meyerhardt, MD, MPH Assistant Professor of Medicine Harvard Medical School Department of Medical Oncology Gastrointestinal Cancer Treatment Center Dana-Farber Cancer Institute Boston, Massachusetts